Metronidazole-induced encephalopathy in a patient with Crohn's disease

  • Kim, J.; 
  • Chun, J.; 
  • Park, J.Y.; 
  • Hong, S.W.; 
  • Lee, J.Y.; 
  • 외 5명
Citations

SCOPUS

12

초록

Metronidazole is a widely used antibiotic for the treatment of anaerobic bacterial infections. Metronidazole-induced encephalopathy (MIEP) is a rare but potentially reversible disease. The mechanism of MIEP remains unclear, and differences in the neurotoxic effects of oral versus intravenous (IV) metronidazole administration have not yet been determined. We report the case of a Crohn's disease (CD) patient who experienced encephalopathy immediately after a single IV dose of metronidazole following long-term exposure to the oral form of the drug. The 64-year-old man with intractable CD experienced a sudden change in mental status, aphasia, and muscle weakness after IV administration of metronidazole. He had previously taken metronidazole orally for 13 years and received intermittent IV metronidazole treatments for CD exacerbation. Brain magnetic resonance imaging (MRI) showed high-intensity signals in the bilateral medial thalamus and the midbrain and pontine tegmentum on fluid-attenuated inversion recovery images. After discontinuation of metronidazole, the high-intensity brain MRI signals resolved and the patient's mental status dramatically improved; however, the patient exhibited mild cognitive dysfunction 2 months after the onset of encephalopathy. © 2017. Korean Association for the Study of Intestinal Diseases. All rights reserved.

키워드

Crohn disease; Drug side effects; Metabolic encephalopathy; Metronidazole
제목
Metronidazole-induced encephalopathy in a patient with Crohn's disease
저자
Kim, J.; Chun, J.; Park, J.Y.; Hong, S.W.; Lee, J.Y.; Kang, J.W.; Hwang, S.; Ko, S.-B.; Im, J.P.; Kim, J.S.
DOI
10.5217/ir.2017.15.1.124
발행일
2017
유형
Article
저널명
Intestinal research
권
15
호
1
페이지
124 ~ 129

파일 다운로드

Thumbnail